Keywords
How to Cite
Abstract
Annotatsion. Our data suggest that a whole-body 18F-FDG PET/CT mammography protocol may be used for staging breast cancer in a single session. This initial assessment of the 18F-FDG PET/CT protocol indicates similar accuracy to MRI for the detection of breast cancer lesions. Although MRI seems to be more accurate when assessing the T stage of the tumor, 18F-FDG PET/CT seems able to more accurately define lesion focality. Although 18F-FDG PET/CT mammography was able to detect axillary lymph node metastases with a high sensitivity, this method cannot soon be expected to replace the combination of clinical examination, ultrasound, and sentinel lymph node biopsy for axillary assessment. Drug therapy remains the main method of complex treatment at these stages. Positron emission tomography (PET) with fluorodeoxyglucose has now been used to assess the effect of the treatment. This method makes it possible to assess changes in the tumor at the cellular level long before morphological manifestations. Thus, a decrease in the accumulation of fluorodeoxyglucose in the tumor by more than 45% of the initial one predicts a complete pathomorphological response to drug therapy with great accuracy.
References
1. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2016 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 236 с.
2. Groheux D., Espi´e M., Giacchetti S. et al. Performance of FDG PET/CT in the clinical management of breast cancer // Radiology. 2013. V. 266. P. 388-405.
3. Wahl R.L., Zasadny K., Helvie M. et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation // J. Clin. Oncol. 1993. V. 11. P. 2101-2111.
4. Boellaard R. Need for standardization of 18FFDG PET/CT for treatment response assessments // J. Nucl. Med. 2011. V. 52 (2). P. 93-100.
5. Cheng X., Li Y., Liu B. et al. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: A meta-analysis // Acta Radiol. 2012. V. 53. P. 615-627.
6. Wang Y., Zhang C., Liu J. et al. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis // Breast Cancer Res. Treat. 2012. V. 131. P. 357-369.
7. Mghanga F.P., Lan X., Bakari K.H. et al. Fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: A meta-analysis // Clin. Breast Cancer. 2013. V. 13. P. 271- 279.
8. Schwarz-Dose J., Untch M., Tiling R. et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F] fluorodeoxyglucose // J. Clin. Oncol. 2009. V. 27. P. 535-541.
9. Berriolo-Riedinger A., Touzery C., Riedinger J.M. et al. [18F] FDGPET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy // Eur. J. Nucl. Med. Mol. Imaging. 2007. V. 34. P. 1915-1924.
10. Garc´ia Garc´ia-Esquinas M., Garc´ia-S´aenz J.A., Arrazola Garc´ia J. et al. 18F-FDG PET-CT imaging in the neoadjuvant setting for stages II-III breast cancer: Association of loco-regional SUVmax with classical prognostic factors // Q. J. Nucl. Med. Mol. Imaging. 2014. V. 58. P. 66-73.
11. Kuerer H.M., Newman L.A., Smith T.L. et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy // J. Clin. Oncol. 1999. V. 17. P. 460-469.
12. von Minckwitz G., Untch M., Blohmer J.U. et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes // J. Clin. Oncol. 2012. V. 30. P. 1796-1804.
13. Schelling M., Avril N., Nahrig J. et al. Positron emission tomography using [(18)F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer // J. Clin. Oncol. 2000. V. 18. P. 1689-1695.
14. Rousseau C., Devillers A., Sagan C. et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F] fluorodeoxyglucose positron emission tomography // J. Clin. Oncol. 2006. V. 24. P. 5366-5372.
15. McDermott G.M., Welch A., Staff R.T. et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET // Breast Cancer Res. Treat. 2007. V. 102. P. 75-84.
16. Kumar A., Kumar R., Seenu V. et al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer // Eur. Radiol. 2009. V. 19. P. 1347-1357.
17. Kolesnikov-Gauthier H., Vanlemmens L., Baranzelli M.C. et al. Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDGPET after the first course // Breast Cancer Res. Treat. 2012. V. 131. P. 517-525.
18. Duch J., Fuster D., Muñoz M. et al. PET/CT with [18F] fluorodeoxyglucose in the assessment of metabolic response to neoadjuvant chemotherapy in locally advanced breast cancer // Q. J. Nucl. Med. Mol. Imaging. 2012. V. 56. P. 291-298.
19. Duch J., Fuster D., Muñoz M. et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer // Eur. J. Nucl. Med. Mol. Imaging. 2009. V. 36. P. 1551-1557. 20. Piccart-Gebhart M.J., Procter M., Leyland-Jones B. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer // N. Engl. J. Med. 2005. V. 353. P. 1659-1672.